Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) – Riverton Roll

AgeX Therapeutics (NYSE:AGE) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares AgeX Therapeutics and Phibro Animal Healths net margins, return on equity and return on assets.

Risk & Volatility

AgeX Therapeutics has a beta of 4.42, indicating that its stock price is 342% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for AgeX Therapeutics and Phibro Animal Health, as provided by MarketBeat.com.

Phibro Animal Health has a consensus price target of $26.60, indicating a potential upside of 5.18%. Given Phibro Animal Healths higher possible upside, analysts plainly believe Phibro Animal Health is more favorable than AgeX Therapeutics.

Insider and Institutional Ownership

17.7% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 50.5% of Phibro Animal Health shares are owned by institutional investors. 3.1% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AgeX Therapeutics and Phibro Animal Healths revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than AgeX Therapeutics.

Summary

Phibro Animal Health beats AgeX Therapeutics on 9 of the 11 factors compared between the two stocks.

About AgeX Therapeutics

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll